TNI BioTech Files Form 10 with SEC
BETHESDA MD. April 22, 2013 -- TNI BioTech, Inc. (PINKSHEETS: TNIB) ( www.tnibiotech.com ), announced it has filed its Form 10 to become a fully reporting public company with the Securities and Exchange Commission.
Some of the highlights of the filing are the acquisition and licensing agreements between TNI BioTech and Dr. Nicholas P. Plotnikoff, Dr. Bernard Bihari, Professor Fengping Shan, Dr. Jill Smith and LDN Research LLC, and Pennsylvania State University. In addition to the patents and licenses, TNI BioTech has obtained the rights to the clinical data, transfer of the IND and orphan drug designations from the U.S. Food & Drug Administration for pancreatic cancer and Crohn’s disease to the Company. Management Believes the orphan drug designation will allow the company to fast track the development of clinical trials for both of these indications in the United States and internationally.
"We are fortunate to have such expert and dedicated leadership in key positions here at TNI BioTech and our affiliate companies," stated Noreen Griffin, CEO of TNI BioTech. "The last few weeks have been a test of our resolve, and we have demonstrated that we are up for the challenge in running a public company." The Form 10 document, financial statements, auditor's footnotes, and opinion letter can be found at the following link on the company's website www.tnibiotech.com .
About TNI Biotech, Inc.
TNI BioTech Inc. is a biotech company with the goal of benefitting patients with chronic and often life-threatening diseases through the activation and rebalancing of the body’s immune system, using our patented immunotherapy.
Our products, technologies and patents are designed to harness the power of the immune system to improve the treatment of cancer, chronic infections such as HIV/AIDS, and autoimmune diseases and, such as Crohn’s disease, other types of inflammatory bowel disease, and multiple sclerosis.
Our most advanced clinical programs involve immunotherapy with methionine-enkephalin (MENK) or low dose naltrexone, which both work by triggering opioid receptors on immune cells, leading to an activation and expansion of various cells of the immune system.
Our proprietary technology, therapies and patents, will be used to treat a wide range of cancers. Our most advanced clinical programs involve immunotherapy that works by augmenting the number and functions of both T cells and natural killer (NK) cells in patients with deficient immune responses associated with advanced cancer or HIV/AIDS, and by rebalancing the immune responses in patients with autoimmune diseases, including Crohn’s disease and multiple sclerosis.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company’s expectations or beliefs concerning future events. Statements containing expressions such as “believes,” “anticipates,” “intends,” or “expects,” used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.
See http://www.tnibiotech.com for more information.
Contact: Global Investment Media
Phone: 310-353-6277
